• Previous attempts to minimize the contribution of the

  2022-04-14

  

  Previous attempts to minimize the contribution of the compensatory changes due to chronic loss of Gcgr, have used temporally-controlled reduction of glucagon levels by alpha-cell ablation, glucagon immunoneutralization, and the use of small molecule or antibody glucagon receptor antagonists [10], [3

• Given the actions of GIP analogues administered

  2022-04-14

  

  Given the actions of GIP analogues administered as a single dose to ob/ob mice, studies were performed to assess their ability to act in vivo as antagonists of GIP-induced insulinotropic and antihyperglycaemic actions. (Ala3)GIP, (Phe3)GIP, (Tyr3)GIP and (Pro3)GIP all counteracted the glucose-loweri

• Although GLP has greater insulin releasing effects at pharma

  2022-04-14

  

  Although GLP-1 has greater insulin-releasing effects at pharmacological concentrations [10], it is apparent that the higher circulating concentrations of GIP combined with more pronounced increase in secretion following feeding make GIP the major physiological incretin [7], [11]. The peptide exerts

• The first report about the activity of ANAM in CACs

  2022-04-14

  

  The first report about the activity of ANAM in CACs it is due to Garcia et al. [19] which treated 16 cancer patients with oral ANAM 50mg once daily vs placebo for 3days followed by a washout EPZ004777 mg of 5–7days and then cross-over to the other group for 3 more days. It was described a weight ga

• It must be noted that while

  2022-04-14

  

  It must be noted that while the accumulated evidence on molecular mechanisms has resulted in well-established experimental methods to externally act on single-cell characteristics and networks, safe and efficient external methods to modify multicellular states are still a matter of basic research. C

• br Acknowledgements Research was funded by

  2022-04-13

  

  Acknowledgements Research was funded by the Natural Sciences and Engineering Council of Canada (NSERC) (Grant #210290) SGF. The funding body played no role in the design or execution of the study. The authors declare no conflict of interest. Introduction HBO2 therapy is the use of 100% oxygen

• br Experimental Procedures Information on

  2022-04-13

  

  Experimental Procedures Information on the materials used in this study and the details of how the in vivo and in vitro assays were performed are provided in Supplemental Information. Acknowledgments This research was supported by the National Research Foundation of Korea (NRF) grant funded b

• Interestingly we have shown that OA required

  2022-04-13

  

  Interestingly, we have shown that OA required FFAR4 to induce osteoblast gene expression in MC3T3-E1 pre-osteoblasts, but not to inhibit osteoclastogenesis in RAW264.7 murine macrophages. As previously suggested, FFAR1 may mediate the effects of OA in osteoclasts. However, FFAR1 has also been shown

• This review is an overview on the ongoing trials

  2022-04-13

  

  This review is an overview on the ongoing trials involving anti-FGF-FGFR therapies (Wu et al., 2013). Pathway FGFR in cancer A recent study comparing more than 4800 tumor tissue samples has shown that 7.1% of all tumor types have genetic alterations in the FGF-FGFR axis. The aberrations perce

• The ability of GPX and other selenoproteins to be

  2022-04-13

  

  The ability of GPX4 and other selenoproteins to be selectively induced by ferroptotic stimuli suggests that the stress-induced increase in the transcription of a number of putative, “antioxidant” selenoproteins is an adaptive homeostatic, but insufficient response to prevent cell death in the face o

• Noticeably aminopyrimidine analogs are the most widely publi

  2022-04-13

  

  Noticeably, aminopyrimidine analogs are the most widely published H4R antagonists and it was Bayer who first disclosed two series of 2-aminopyrimidine compounds possessing significant H4R functional activity. Subsequently, further 2-aminopyrimidine H4R antagonists were published by Pfizer (ZPL-38937

• br STAR Methods br Acknowledgments The authors would

  2022-04-13

  

  STAR★Methods Acknowledgments The authors would like to acknowledge Genentech DNA Sequencing, Biologics Resource, Oligo, FACS, and Bioinformatics groups for their help with the project. Our thanks to Craig Cumming and Sophia Maund for facilitating our access to large-scale mutation data. We als

• Among RASs observed in patients from group

  2022-04-13

  

  Among RASs observed in patients from group 2, RAS T54S was identified in one patient infected with subtype 1b. This mutation had been shown to cause resistance to boceprevir and telaprevir, but not to simeprevir [36]. This was confirmed here since this patient achieved SVR after 12 weeks of treatmen

• Measured physicochemical water parameters including conducti

  2022-04-13

  

  Measured physicochemical water parameters including conductivity, suspended solids and nutrient load along the studied sites (Table 1) were high compared to levels usually found in undisturbed rivers within Europe (Chapman and Kimstach, 1996). In particular conductivity, suspended solids and phospha

• br Medium and long chain fatty acid

  2022-04-12

  

  Medium- and long-chain fatty Physostigmine hemisulfate receptor receptors Clinical studies of ω3 fatty acids Clinical studies have established that dietary intake of ω3 fatty acids should be around 4g/day for treating very high triglyceride levels (≥5.7mmol/L) [36]. Low-dose supplementation wi

16188 records 460/1080 page Previous Next First page 上5页 456457458459460 下5页 Last page